Catalyst
Slingshot members are tracking this event:
Regeneron Pharmaceuticals (REGN) to submit to FDA for DUPIXENT (dupilumab) in treating asthma
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| REGN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 02, 2018
Occurred Source:
http://files.shareholder.com/downloads/REGN/5250934809x0x973109/0F96ACB7-CB55-494A-B4F9-33E04A49D3B2/REGN_News_2018_3_2_General_Releases.pdf
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Dupixent, Dupilumab, Fda Submission, Asthma
